Neoadjuvant Chemotherapy and Radiochemotherapy: Is There a Survival Advantage for Pancreatic Cancer Patients?

Pancreatic Cancer, Cystic Neoplasms and Endocrine Tumors: Diagnosis and Management

Volumn , Issue , 2015, Pages 103-119

  Tsai, Susan ^a   George, Ben ^a   Christians, Kathleen K ^a   Evans, Douglas B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Adjuvant chemotherapy; Borderline resectable; Neoadjuvant chemoradiotherapy; Pancreatic cancer

Indexed keywords

EID: 84978698094     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118307816.ch13     Document Type: Chapter

References (53)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011; Based on November 2010 SEER data submission posted to the SEER Web site, 2011 [cited August 31 2014]; Available from: http://seer.cancer.gov/ csr/1975_2008/.
2. Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades. Annals of Surgical Oncology. 2012;19(1):169-175.
3. Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Annals of Surgery. 2007;246(5):734-740.
4. Tepper J, Nardi G, Sutt H. Carcinoma of the pancreas: review of MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy. Cancer. 1976;37(3):1519-1524.
5. Van den Broeck A, Sergeant G, Ectors N, Van Steenbergen W, Aerts R, Topal B. Patterns of recurrence after curative resection of pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology. 2009;35(6):600-604.
6. Westerdahl J, Andrén-Sandberg A, Ihse I. Recurrence of exocrine pancreatic cancer-local or hepatic? Hepato- Gastroenterology. 1993;40(4):384-387.
7. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Archives of Surgery (Chicago, Ill.: 1960). 1985;120(8): 899-903.
8. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Annals of Surgery. 1999;230(6):776-782; discussion 782-784.
9. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. The New England Journal of Medicine. 2004;350(12):1200-1210.
10. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA: The Journal of the American Medical Association. 2007;297(3):267-277.
11. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA: The Journal of the American Medical Association. 2010;304(10):1073-1081.
12. Regine WF, Winter KW, Abrams R. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. Journal of Clinical Oncology. 2006; 24(18S):4007.
13. Regine WF, Winter KA, Abrams R, et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Annals of Surgical Oncology. 2011;18(5): 1319-1326.
14. Abrams RA, Lowy AM, O'Reilly EM, Wolff RA, Picozzi VJ, Pisters PW. Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement. Annals of Surgical Oncology. 2009;16(7): 1751-1756.
15. NCCN. NCCN Practice Guidelines: Pancreatic Adenocarcinoma. National Comprehensive Cancer Network. 2011; [cited August 31, 2014]; Available from: http://www .nccn.org.
16. Evans DB, Rich TA, Byrd DR, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Archives of Surgery (Chicago, Ill.: 1960). 1992;127(11):1335-1339.
17. Pilepich MV, Miller HH. Preoperative irradiation in carcinoma of the pancreas. Cancer. 1980;46(9):1945-1949.
18. Takahashi H, Ogawa H, Ohigashi H, et al. Preoperative chemoradiation reduces the risk of pancreatic fistula after distal pancreatectomy for pancreatic adenocarcinoma. Surgery. 2011;150(3):547-556.
19. Raut CP, Evans DB, Crane CH, Pisters PW, Wolff RA. Neoadjuvant therapy for resectable pancreatic cancer. Surgical Oncology Clinics of North America. 2004;13(4): 639-661, ix.
20. Willett CG, Lewandrowski K, Warshaw AL, Efird J, Compton CC. Resection margins in carcinoma of the head of the pancreas. Implications for radiation therapy. Annals of Surgery. 1993;217(2):144-148.
21. Pisters PW, Hudec WA, Lee JE, et al. Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. Journal of Clinical Oncology. 2000;18(4): 860-867.
22. Hoffman JP, Weese JL, Solin LJ, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. American Journal of Surgery. 1995;169(1):71-77; discussion 77-78.
23. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. Journal of Clinical Oncology. 1998;16(1):317-323.
24. Staley CA, Lee JE, Cleary KR, et al. Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. American Journal of Surgery. 1996;171(1):118-124; discussion 124-125.
25. Pisters PW, Abbruzzese JL, Janjan NA, et al. Rapidfractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. Journal of Clinical Oncology. 1998;16(12):3843-3850.
26. White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Annals of Surgical Oncology. 2001;8(10): 758-765.
27. Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology. 2008;26(21):3496-3502.
28. Talamonti MS, Small W Jr, Mulcahy MF, et al. A multiinstitutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Annals of Surgical Oncology. 2006;13(2):150-158.
29. Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head. Journal of Clinical Oncology. 2008;26(21): 3487-3495.
30. Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Medicine. 2010;7(4): e1000267.
31. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. Journal of the American College of Surgeons. 2008;206(5):833-846; discussion 846-848.
32. Patel M, Hoffe S, Malafa M, et al. Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer. Journal of Surgical Oncology. 2011;104(2):155-161.
33. McClaine RJ, Lowy AM, Sussman JJ, Schmulewitz N, Grisell DL, Ahmad SA. Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer. HPB: The Official Journal of the International Hepato Pancreato Biliary Association. 2010;12(1):73-79.
34. Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Annals of Surgical Oncology. 2011;18(3): 619-627.
35. Fine RL, Fogelman DR, Schreibman SM, et al. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for meta static pancreatic cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology. 2008;61(1):167-175.
36. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England Journal of Medicine. 2011;364(19):1817-1825.
37. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. Journal of Clinical Oncology. 2011;29(34):4548-4554.
38. Nakahira S, Nakamori S, Tsujie M, et al. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. International Journal of Cancer. 2007;120(6):1355-1363.
39. Ashida R, Nakata B, Shigekawa M, et al. Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer. Journal of Experimental and Clinical Cancer Research. 2009;28:83.
40. Akita H, Zheng Z, Takeda Y, et al. Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. Oncogene. 2009;28(32):2903-2909.
41. Aschele C, Lonardi S, Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treatment Reviews. 2002;28(1): 27-47.
42. Koopman M, Venderbosch S, van Tinteren H, et al. Predictive and prognostic markers for the outcome of chemotherapy in advanced colorectal cancer, a retrospective analysis of the phase III randomised CAIRO study. European Journal of Cancer. 2009;45(11):1999-2006.
43. Katz MH, Wang H, Fleming JB, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Annals of Surgical Oncology. 2009;16(4): 836-847.
44. Griffin JF, Smalley SR, Jewell W, et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer. 1990;66(1):56-61.
45. Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II study. Cancer. 1993;72(7):2124-2133.
46. Pisters PW, Wolff RA, Janjan NA, et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. Journal of Clinical Oncology. 2002;20(10):2537-2544.
47. Moutardier V, Magnin V, Turrini O, et al. Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 2004;60(2): 437-443.
48. Mornex F, Girard N, Delpero JR, Partensky C. Radiochemotherapy in the management of pancreatic cancer-part I: neoadjuvant treatment. Seminars in Radiation Oncology. 2005;15(4):226-234.
49. Spratlin J, Sangha R, Glubrecht D, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clinical Cancer Research. 2004; 10(20):6956-6961.
50. Giovannetti E, Del Tacca M, Mey V, et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Research. 2006;66(7):3928-3935.
51. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136(1):187-195.
52. Kim R, Tan A, Lai KK, et al. Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer. 2011;117(14):3126-3134.
53. Morinaga S, Nakamura Y, Watanabe T, et al. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Annals of Surgical Oncology. 2012;19(Suppl 3):S558-S564.